Drug combination shows promise in preclinical models of triple negative breast cancer
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent ...
Dec 10, 2019
0
3